A detailed history of Geode Capital Management, LLC transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 4,683,042 shares of BLUE stock, worth $1.83 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,683,042
Previous 4,516,271 3.69%
Holding current value
$1.83 Million
Previous $4.43 Million 44.97%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$0.47 - $1.35 $78,382 - $225,140
166,771 Added 3.69%
4,683,042 $2.44 Million
Q2 2024

Aug 09, 2024

BUY
$0.85 - $1.26 $168,303 - $249,485
198,004 Added 4.59%
4,516,271 $4.43 Million
Q1 2024

May 13, 2024

BUY
$0.91 - $1.75 $1.77 Million - $3.41 Million
1,948,583 Added 82.23%
4,318,267 $5.53 Million
Q4 2023

Feb 13, 2024

BUY
$1.32 - $4.83 $195,610 - $715,757
148,190 Added 6.67%
2,369,684 $3.27 Million
Q3 2023

Nov 13, 2023

BUY
$3.02 - $4.05 $5,242 - $7,030
1,736 Added 0.08%
2,221,494 $6.75 Million
Q2 2023

Aug 11, 2023

BUY
$2.79 - $5.03 $337,913 - $609,213
121,116 Added 5.77%
2,219,758 $7.3 Million
Q1 2023

May 15, 2023

BUY
$3.14 - $8.22 $1.46 Million - $3.83 Million
465,935 Added 28.54%
2,098,642 $6.67 Million
Q4 2022

Feb 13, 2023

BUY
$5.77 - $8.49 $1.15 Million - $1.69 Million
199,183 Added 13.89%
1,632,707 $11.3 Million
Q3 2022

Nov 14, 2022

BUY
$3.75 - $7.39 $659,670 - $1.3 Million
175,912 Added 13.99%
1,433,524 $9.07 Million
Q2 2022

Aug 12, 2022

BUY
$2.94 - $5.23 $401,118 - $713,555
136,435 Added 12.17%
1,257,612 $5.21 Million
Q1 2022

May 13, 2022

SELL
$4.07 - $10.6 $473,890 - $1.23 Million
-116,435 Reduced 9.41%
1,121,177 $5.44 Million
Q4 2021

Feb 11, 2022

BUY
$8.96 - $16.31 $637,925 - $1.16 Million
71,197 Added 6.1%
1,237,612 $12.4 Million
Q3 2021

Nov 12, 2021

SELL
$11.24 - $21.0 $690,574 - $1.29 Million
-61,439 Reduced 5.0%
1,166,415 $22.3 Million
Q2 2021

Aug 13, 2021

BUY
$18.04 - $22.09 $7.23 Million - $8.85 Million
400,610 Added 48.43%
1,227,854 $39.3 Million
Q1 2021

May 12, 2021

BUY
$16.59 - $33.89 $213,679 - $436,503
12,880 Added 1.58%
827,244 $24.9 Million
Q4 2020

Feb 12, 2021

BUY
$27.5 - $37.92 $1.44 Million - $1.99 Million
52,368 Added 6.87%
814,364 $35.2 Million
Q3 2020

Nov 13, 2020

SELL
$34.44 - $43.75 $171,476 - $217,831
-4,979 Reduced 0.65%
761,996 $41.1 Million
Q2 2020

Aug 13, 2020

BUY
$27.12 - $45.97 $2.91 Million - $4.93 Million
107,247 Added 16.26%
766,975 $46.8 Million
Q1 2020

May 14, 2020

BUY
$26.16 - $63.5 $586,114 - $1.42 Million
22,405 Added 3.52%
659,728 $30.3 Million
Q4 2019

Feb 13, 2020

BUY
$46.96 - $61.67 $871,953 - $1.15 Million
18,568 Added 3.0%
637,323 $55.9 Million
Q3 2019

Nov 12, 2019

BUY
$59.47 - $93.1 $149,864 - $234,612
2,520 Added 0.41%
618,755 $56.8 Million
Q2 2019

Aug 14, 2019

BUY
$75.84 - $105.21 $2.11 Million - $2.93 Million
27,883 Added 4.74%
616,235 $78.4 Million
Q1 2019

May 14, 2019

BUY
$64.44 - $104.11 $2.31 Million - $3.73 Million
35,793 Added 6.48%
588,352 $92.6 Million
Q4 2018

Feb 13, 2019

BUY
$59.1 - $93.26 $2.55 Million - $4.03 Million
43,192 Added 8.48%
552,559 $54.8 Million
Q3 2018

Nov 13, 2018

BUY
$88.86 - $117.49 $2.52 Million - $3.33 Million
28,338 Added 5.89%
509,367 $74.4 Million
Q2 2018

Aug 14, 2018

BUY
$99.64 - $127.59 $756,666 - $968,918
7,594 Added 1.6%
481,029 $75.5 Million
Q1 2018

May 15, 2018

BUY
$105.8 - $150.94 $1.95 Million - $2.78 Million
18,438 Added 4.05%
473,435 $80.8 Million
Q4 2017

Feb 13, 2018

BUY
$81.25 - $130.7 $3.05 Million - $4.91 Million
37,588 Added 9.01%
454,997 $81 Million
Q3 2017

Nov 14, 2017

BUY
$57.74 - $91.42 $2.54 Million - $4.02 Million
44,027 Added 11.79%
417,409 $57.3 Million
Q2 2017

Aug 14, 2017

BUY
N/A
373,382
373,382 $39.2 Million

Others Institutions Holding BLUE

About bluebird bio, Inc.


  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $30.1M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.